Company / R&D Expense
KalVista Pharmaceuticals, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$71.7M
FY2025
5-year range
$70.2M / $86.2M
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
#164 of 210
Health Care
What the data says
KalVista Pharmaceuticals, Inc.'s r&d expense of $72M is lower than 78% of companies in the Health Care sector (FY2025). R&D Expense has fluctuated over the past 10 years, ranging from $13M in FY2019 to $86M in FY2023.
Based on SEC 10-K filings.
$72M in FY2025 with a 5-year CAGR of +11.7%.
Declined from $86M to $72M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -3.7%
- 5-Year CAGR
- +11.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 210This company $71.7M Sector average $644.0M
▼
-88.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.7%, indicating consistent growth.
- In FY2025, r&d expense increased 0.0% year-over-year.
- Ranks #164 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $71.7M | +0.0% |
| FY2024 | $71.7M | -16.8% |
| FY2023 | $86.2M | +7.3% |
| FY2022 | $80.3M | +14.4% |
| FY2021 | $70.2M | +70.0% |
| FY2020 | $41.3M | +226.0% |
| FY2019 | $12.7M | -13.6% |
| FY2018 | $14.7M | -19.6% |
| FY2017 | $18.2M | +44.0% |
| FY2016 | $12.7M | +52.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026